How to select a biosimilar

European Journal of Hospital Pharmacy

Volumn 20, Issue 5, 2013, Pages 275-286

  Boone, Niels ^a   van der Kuy, Hugo ^a   Scott, Mike ^b   Mairs, Jill ^b   Krämer, Irene ^c   Vulto, Arnold ^d   Janknegt, Rob ^a  

^a Zuyderland Medical Centre   (Netherlands)

^b ANTRIM AREA HOSPITAL   (United Kingdom)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; EPOETIN ALPHA HEXAL; HUMAN GROWTH HORMONE; MONOCLONAL ANTIBODY; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; GOOD CLINICAL PRACTICE; HEALTH CARE DELIVERY; HUMAN; IMMUNOGENICITY; NONHUMAN; QUALITY CONTROL;

EID: 84884366767     PISSN: 20479956     EISSN: 20479964     Source Type: Journal    
DOI: 10.1136/ejhpharm-2013-000370     Document Type: Article

References (56)

1. European Commission. What you need to know about biosimilar medicinal products. European Commission. 2013. http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_report_en.pdf (accessed 3 Jul 2013).
2. Declerck PJ, Simoens S. A European perspective on the market accessibility of biosimilars. Biosimilars 2012;2:33-40.
3. Misra A. Are biosimilars really generics? Expert Opin Biol Ther 2010;10:489-94.
4. Krämer I, Tredree R, Vulto A. Points to consider in the evaluation of biopharmaceuticals. Eur J Hosp Pharm Prac 2008;14:73-6.
5. Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotech 2006;22:1383-91.
6. Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharm 2004;3:43-7.
7. Büttel IC, Chamberlain P. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 2011;39:100-9.
8. European Medicines Agency. Guideline on comparability of medicinal products containing biotechnology derived products as active substance non-clinical and clinical issues. European Medicines Agency. April 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500144124.pdf (accessed 3 Jul 2013).
9. Zuniga L, Calvo B. Biosimilars: pharmacovigilance and risk management. Pharmacoepidemiol Drug Saf 2010;19:661-9.
10. Pro Pharma Communications International, GaBI Online-Generics and Biosimilars Initiative. Biosimilars-not-so-far-so-fast. GaBI Online. 18 March 2013. http://www.genengnews.com/insight-and-intelligence/biosimilars-not-so-far-so-fast/77899781/ (accessed 9 Apr 2013).
11. Rovira J, Lindner L, Gimenez E, et al. Biosimilars in the European market. GaBI J 2013;2:30-5.
12. Food and Drug Administration. Guidance for industry on biosimilars. Q & As regarding implementation of the BPCI Act of 2009: Questions and Answers Part I, Q.I.14. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm259809.htm (accessed 15 Aug 2013).
13. Pro Pharma Communications International, GaBI Online-Generics and Biosimilars Initiative. Interchangeability not covered in FDA draft biosimilar guidance. GaBI Online. 17 February 2012. http://www.gabionline.net/Guidelines/Interchangeability-not-covered-in-FDA-draft-biosimilar-guidance (accessed 18 Apr 2013).
14. European Medicines Agency. Questions and answers on biosimilar medicines (similar biologic medicinal products). European Medicines Agency. 27 September 2012. http://www.emea.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf. (accessed 27 Apr 2013).
15. Zuñiga L, Calvo B. Regulatory aspects of biosimilars in Europe. Trends Biotechnol 2009;27:385-7.
16. Pharma and Healthcare Insight. Dutch health insurers to reimburse biosimilars. 25 September 2009. http://www.pharmaceuticalsinsight.com/file/81624/dutch-health-insurers-to-reimburse-biosimilars.html (accessed 18 Apr 2013).
17. Janknegt R, Steenhoek A. The System of Objectified Judgement Analysis. A tool in rational drug selection for formulary purposes. Drugs 1997;53:550-62.
18. Brenninkmeijer R, Mairs J, Timoney M, et al. InforMatrix as an alternative tool in rational and transparent drug-decision making. Expert Opin Pharmacother 2007;8 (Suppl 1):S31-6.
19. Scott M, Timoney M, Mairs J, et al. Safe Therapeutic Economic Pharmaceutical Selection (STEPS): development, introduction and use in Northern Ireland. Expert Opin Pharmacother 2007;8(Suppl 1):S57-63.
20. European Medicines Agency. Pharmaceutical Quality System (ICHQ10). European Medicines Agency. 21 January 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002871.pdf (accessed 17 Apr 2013).
21. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guidance for industry Q8 (R2) Pharmaceutical development. Food and Drug Administration. 10 November 2009. http://www.fda.gov/downloads/Drugs/Guidances/ucm073507.pdf (accessed 17 Apr 2013).
22. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guidance for industry Q9 Quality risk management. Food and Drug Administration. June 2006. http://www.fda.gov/downloads/Drugs/Guidances/ucm073511.pdf (accessed 17 Apr 2013).
23. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guidance for industry Q10 Pharmaceutical quality system. Food and Drug Administration. April 2009. http://www.fda.gov/downloads/Drugs/Guidances/ucm073517.pdf (accessed 17 Apr 2013).
24. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guidance for industry Q11 Development and manufacture of drug substances. Food and Drug Administration. November 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM261078.pdf (accessed 17 Apr 2013).
25. European Medicines Agency. CPMP/ICH/365/96, ICH Topic Q6B Specifications: Test procedures and acceptance criteria for biotechnological/biological products. September 2009. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002824.pdf (accessed 17 Apr 2013).
26. European Parliament. Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011. European Commission. 8 June 2011. http://ec.europa.eu/health/files/eudralex/vol-1/dir_2011_62/dir_2011_62_en.pdf (accessed 17 Apr 2013).
27. European Parliament. Commission Directive 91/356/EEC of 13 June 1991 laying down the principles and guidelines of good manufacturing practice for medicinal products for human use. EUR-Lex. 13 June 1991. http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31991L0356:en:NOT (accessed 25 Apr 2013).
28. European Parliament. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. EUR-Lex. 4 April 2001. http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32001L0020:en:NOT (accessed 25 Apr 2013).
29. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Good manufacturing practice guide for active pharmaceutical ingredients Q7. 10 November 2000. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q7/Step4/Q7_Guideline.pdf (accessed 17 Apr 2013).
30. European Medicines Agency. EMA/940451/2011, EMA Procedural advice for users of the centralised procedure for similar biological medicinal products applications. March 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/WC500125166.pdf (accessed 17 Apr 2013).
31. European Medicines Agency. Omnitrope EPAR-scientific discussion. 23 April 2008. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Scientific_Discussion/human/000607/WC500043692.pdf (accessed 25 Apr 2013).
32. European Medicines Agency. Ratio orgrastim EPAR-scientific discussion. 29 September 2009. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/000825/WC500047793.pdf (accessed 25 Apr 2013).
33. European Medicines Agency. EMEA/INS/GMP/23020/2007, An analysis of quality product defects in the centralised procedure. European Medicines Agency. 18 January 2007. http://www.emea.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004420.pdf (accessed 17 Apr 2013).
34. Boven K, Knight J, Bader F, et al. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant 2005;20(Suppl 3):33-40.
35. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Comparability of biotechnological/biological products subject to changes in their manufacturing process. 18 November 2004. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf (accessed 20 Apr 2013).
36. Schiestl M, Stangler T. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011;29:310-12.
37. European Medicines Agency. Procedural steps taken and scientific information after authorization/Steps taken after authorisation when a cutoff date has been used. http://www.ema.europa.eu > 'Find Medicine' > [name] > 'Assessment history' > [name]: EPAR - Procedural steps taken and scientific information after authorisation; for products licensed before the deadline also refer to '[name]: EPAR -Steps taken after authorisation when a cutoff date has been used' (accessed 20 Apr 2013).
38. European Medicines Agency. Filgrastim-Hexal EPAR-Public assessment report. 6 February 2009. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/000918/WC500022471.pdf (accessed 27 Apr 2013).
39. European Medicines Agency. Nivestim EPAR-public assessment report. 8 June 2010. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/001142/WC500093664.pdf (accessed 27 Apr 2013).
40. European Medicines Agency. EMEA/CHMP/EWP/192217/2009, Guideline on bioanalytical method validation. 21 July 2011. http://www.ema.europa.eu/docs/en_ GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf (accessed 17 Apr 2013).
41. European Generic Medicines Association. Biosimilars handbook second edition. Brussels: Sage, 2011:29.
42. European Medicines Agency. EMA/410/01, Note for Guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via medicinal products. 5 March 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003700.pdf (accessed 27 Apr 2013).
43. European Medicines Agency. EMA/121340/2011 Reflection paper on ethical and GCP aspects of clinical trials of medicinal products for human use conducted outside of the EU/EEA and submitted in marketing authorisation applications to the EU Regulatory Authorities. 16 April 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/WC500125437. pdf (accessed 17 Apr 2013).
44. Bee JS, Randolph TW, Carpenter JF, et al. Effects of surfaces and leachables on the stability of biopharmaceuticals. J Pharm Sci 2011 Published Online First: 26 April 2011 doi:10.1002/jps.22597.
45. World Health Organization. Annex 5 Guidelines on good distribution practices for pharmaceutical products. World Health Organization. 2010. http://www.who.int/medicines/areas/quality_safety/quality_assurance/GoodDistribution PracticesTRS957Annex5.pdf (accessed 3 Jul 2013).
46. European Parliament. 2013/C68/01 Guidelines of 7 March 2013 on good distribution practice of medicinal products for human use. EUR-Lex. 8 March 2013. http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2013:068:0001:0014:EN:PDF (accessed 3 Jul 2013).
47. Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis 2013;72:315-18.
48. Sharma B. Immunogenicity of therapeutic proteins. Part 1: Impact of product handling. Biotech Adv 2007;25:310-17.
49. Sharma B. Immunogenicity of therapeutic proteins. Part: 2: Impact of container closure. Biotech Adv 2007;25:318-24.
50. Barbosa M. Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters. Drug Discov Today 2011;16:345-53.
51. European Medicines Agency. EMEA/CHMP/BMWP/14327/2006, Guidelines on immunogenicity assessment of biotechnology-derived therapeutic proteins. 13 December 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf (accessed 17 Apr 2013).
52. European Parliament. Regulation EC 726/2004 of the European Parliament and of the Council of 31 March 2004, laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. European Medicines Agency. 30 April 2004. http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:136:0001:0033:en:PDF (accessed 27 Apr 2013).
53. European Parliament. Commission Regulation (EC) No 540/951995 March 10 laying down the arrangements for reporting suspected unexpected adverse reactions which are not serious, whether arising in the Community or in a third country, to medicinal products for human or veterinary use authorized in accordance with the provisions of Council Regulation (EEC) No 2309/93.
54. European Commission. 1995. http://ec.europa.eu/health/files/eudralex/vol-1/reg_1995_540/reg_1995_540_en.pdf (accessed 27 Apr 2013).
55. European Parliament. Volume 9A of the Rules Governing Medicinal Products in the European Union. Guidelines on pharmacovigilance for medicinal products for human use. European Commission. September 2008. http://ec.europa.eu/health/files/eudralex/vol-9/pdf/vol9a_09-2008_en.pdf (accessed 27 Apr 2013).
56. European Medicines Agency. EMA/CHMP/BMWP/403543/2010. Guideline on similar biological medicinal products containing monoclonal antibodies-non-clinical and clinical issues. 30 May 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf (accessed 17 Apr 2013).